Click here to close now.

SYS-CON MEDIA Authors: Yeshim Deniz, Pat Romanski, Carmen Gonzalez, Liz McMillan, Roger Strukhoff

News Feed Item

Pressure BioSciences, Inc. Reports Strong Fourth Quarter and Fiscal Year 2013 Financial Results

Total Revenue Up 64% (Q/Q) and 21% (Y/Y)

SOUTH EASTON, Mass., April 1, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three-month period and fiscal year ended December 31, 2013 and provided a business update.

Total revenue for the fourth quarter of 2013 was $354,052 compared to $216,032 for the same period in 2012, a 64% increase. Revenue from the sale of products and services was $300,628 for Q4 2013 compared to $122,285 for the same period in 2012, a 146% increase.  Grant revenue in Q4 2013 was $53,424 compared to $93,747 for the same period in the prior year.  Sales of consumables were $52,968 for the three months ended December 31, 2013 compared to $18,624 for the same period in 2012, an increase of 184%.

Operating loss for the fourth quarter of 2013 decreased to $900,110 from $1,129,750 for the same period in 2012, a reduction of 20%.  Contributing to this decrease in operating loss was a quarter over quarter decrease in general and administrative expenses of $268,105, or 30%.

Loss per common share (basic and diluted) was $0.16 for the 2013 fourth quarter compared to $0.10 for the same period in 2012.  The additional loss per common share was due primarily to the change in the fair value of the derivative instruments in Q4 2013.

Total revenue for the fiscal year 2013 was $1,503,288 compared to $1,238,217 for the fiscal year 2012, a 21% increase.  Revenue from the sale of products and services was $1,046,678 for FY 2013 compared to $809,308 for FY 2012, a 29% increase.  Grant revenue in FY 2013 was $456,610 compared to $428,909 for FY 2012.  Sales of consumables were approximately $157,676 for FY 2013 compared to approximately $85,493 for FY 2012, an increase of 84%.

Operating loss for the fiscal year 2013 decreased to $3,327,192 from $3,463,642 for the fiscal year 2012, a reduction of 4%.  Contributing to this decrease in operating loss were decreases in total operating expenses of $22,792 and increased gross margin of $113,658.

Loss per common share (basic and diluted) was $0.44 for 2013 compared to $0.43 for the same period in 2012. 

Richard P. Thomley, Chief Financial Officer of PBI, said: "In addition to strong quarter over quarter (Q4 2013 vs. Q4 2012) revenue increases, both total revenue and products and services revenue showed substantive sequential increases for the year (FY 2013 vs. FY 2012), posting gains of 21% and 29%, respectively. We achieved these results while also decreasing operating expenses. We believe that our financial performance for the fourth quarter and fiscal year 2013 reflect PBI's significant progress in our stated goal of developing a sound financial roadmap moving forward."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "During 2013, and the first three months of 2014, we achieved a number of notable financial and operational successes, including:

  • We closed the first three tranches ($2.8M) of our Series K PIPE (initial goal $1.5M)
  • We released our ultra-high pressure HUB880 instrument system to the market on time (Q1 2014)
  • We closed our $2.0M Series J PIPE, slightly over-subscribed at $2.04M
  • We reported increases in total revenue for Q1, Q2, Q3, and Q4 2013 vs. same quarters in 2012
  • We announced a Core Technology Breakthrough enabling our PCT Platform to develop integration with the dominant laboratory high-throughput robotic pipetting and automation footprint used worldwide
  • We reported on independent studies that showed our novel instrument systems could potentially (i) generate new insights into protein structure and function (for biomarker discovery and drug design); (ii) greatly accelerate rape kit testing; (iii) generate a new understanding of diseases and disorders related to the gastrointestinal tract through non-invasive means; and (iv) offer advantages in cancer, stem cell, and heart disease studies."  

Mr. Schumacher continued: "We believe that our product and services revenue will continue to increase in 2014 and beyond; that the distinct advantages of our pressure cycling-based products will continue to be reported by scientists worldwide; that the number of applications and thus fields of use for our products will continue to increase; and that we will be successful in continuing to raise the funds as required, to help us achieve our goal of financial self-sufficiency and profitability, with steadily increasing shareholder value as we move forward."

Earnings Call

The Company will hold an Earnings Conference Call at 4:15 PM EDT on Tuesday, April 1, 2014.  To attend this teleconference via telephone: Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International). Verbal Passcode (to be given to the operator: VS78313).  Conference ID:  880058.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery, drug discovery & design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.    

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward looking-statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter and fiscal year ended December 31, 2013 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com 
Please visit us on Facebook, LinkedIn, and Twitter.



Investor Contacts:


Richard T. Schumacher, President & CEO, Pressure BioSciences, Inc.

(508) 230-1828 (T)

Richard P. Thomley, Chief Financial Officer, Pressure BioSciences, Inc.

(508) 230-1828 (T)

Howard Gostfrand, President, American Capital Ventures

(858) 568-7059 (T)

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)






For the Three Months Ended





December 31,





2013


2012








Revenue:






Products, services, other


$300,628


$122,285


Grant revenue


53,424


93,747



Total revenue


354,052


216,032








Costs and expenses:






Cost of products and services


203,460


120,329


Research and development


248,284


189,988


Selling and marketing


179,114


144,057


General and administrative


623,304


891,409



Total operating costs and expenses


1,254,162


1,345,782










Operating loss


(900,110)


(1,129,750)








Other income (expense):






Interest expense, net


(109,642)


(62,350)


Other income (expense)


(320,292)


(36,322)


Change in fair value of derivative liabilities


(235,759)


144,840



Total other income (expense)


(665,693)


(46,168)









Loss before income taxes


(1,565,803)


(1,083,582)


Income tax benefit


-


2,014


Net loss


(1,565,803)


(1,081,568)


Accrued and deemed dividend on convertible preferred stock


(397,492)


(54,276)


Net loss applicable to common shareholders


$(1,963,295)


$(1,135,844)
















Net loss per share attributable to common stockholders - basic and

diluted

$(0.16)


$(0.10)









Weighted average common stock shares outstanding used in the

basic and diluted net loss per share calculation


11,955,789


11,804,368

 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

(AUDITED)






For the Year Ended





December 31,





2013


2012








Revenue:






Products, services, other


$1,046,678


$809,308


Grant revenue


456,610


428,909



Total revenue


1,503,288


1,238,217








Costs and expenses:






Cost of products and services


567,828


416,415


Research and development


1,035,426


965,623


Selling and marketing


752,288


714,635


General and administrative


2,474,938


2,605,186



Total operating costs and expenses


4,830,480


4,701,859










Operating loss


(3,327,192)


(3,463,642)








Other income (expense):






Interest expense, net


(339,818)


(133,417)


Other income (expense)


(531,130)


-


Change in fair value of derivative liabilities


113,713


144,840



Total other income (expense)


(757,235)


11,423









Loss before income taxes


(4,084,427)


(3,452,219)


Income tax benefit


-


2,014


Net loss


(4,084,427)


(3,450,205)


Accrued and deemed dividends on convertible preferred stock


(1,163,022)


(950,010)


Net loss applicable to common shareholders


$(5,247,449)


$(4,400,215)
















Net loss per share attributable to common stockholders - basic and

diluted

$(0.44)


$(0.43)









Weighted average common stock shares outstanding used in the

basic and diluted net loss per share calculation


11,821,870


10,154,175

 

 

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(AUDITED)






December 31,


December 31,

ASSETS

2013


2012

CURRENT ASSETS





Cash and cash equivalents

$31,417


$1,461


Accounts receivable

147,635


216,265


Inventories, net of $50,000 reserve

736,676


923,362


Prepaid income taxes

7,381


7,381


Prepaid expenses and other current assets

85,573


83,435


      Total current assets

1,008,682


1,231,904

PROPERTY AND EQUIPMENT, NET

58,102


30,282


Deposits

-


6,472


Intangible assets, net

36.498


85,130

TOTAL ASSETS

$1,103,282


$1,353,788


LIABILITIES AND STOCKHOLDERS' DEFICIT




CURRENT LIABILITIES





Accounts payable

$1,102,772


$1,199,846


Accrued employee compensation

149,333


119,338


Accrued professional fees and other

615,244


267,936


Deferred revenue

28,189


46,466


Promissory note

75,000


75,000


Dividend liability

-


60,000


Related party debt

25,182


98,675


Convertible debt, net of debt discount of $331,806 at Dec. 31, 2013

 and $0 at Dec. 31, 2012

281,796


863,004


Other debt

89,989


-


Warrant derivative liability

344,570


160,812


Conversion option liability

356,197


-


      Total current liabilities

3,068,272


2,891,077

LONG TERM LIABILITIES





Deferred revenue

2,785


2,487

TOTAL LIABILITIES

3,071,057


2,893,564

STOCKHOLDERS' DEFICIT





Series D convertible preferred stock, $.01 par value; 850 shares authorized;

300 shares issued and outstanding on Dec. 31, 2013 and Dec. 31, 2012

3


3


Series G convertible preferred stock, $.01 par value; 240,000 shares authorized;

145,320 shares issued and outstanding on Dec. 31, 2013 and at Dec. 31, 2012

1,453


1,453


Series H convertible preferred stock, $.01 par value; 10,000 shares authorized

10,000 shares issued and outstanding on Dec. 31, 2013 and 0 at Dec. 31, 2012

100


-


Series J convertible preferred stock, $.01 par value; 6,250 shares authorized;

5,087.5 shares and 0 shares issued and outstanding on Dec. 31, 2013 and on

Dec. 31, 2012, respectively

51


-


Series K convertible preferred stock, $.01 par value; 15,000 shares authorized;

4,000 shares issued and outstanding on Dec. 31, 2013 and 0 at Dec. 31, 2012

40


-


Common stock, $.01 par value; 50,000,000 shares authorized;

 12,024,267 and 12,149,267 shares issued and outstanding on Dec. 31, 2013

and on Dec. 31, 2012, respectively

120,243


121,493


Warrants to acquire preferred stock and common stock

4,267,402


3,015,996


Additional paid-in capital

19,509,921


15,940,818


Accumulated deficit

(25,866,988)


(20,619,539)


      Total stockholders' deficit

(1,967,775)


(1,539,776)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$1,103,282


$1,353,788

 

SOURCE Pressure BioSciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, June 9-11, 2015, at the Javits Center in New York City. Learn what is going on, contribute to the discussions, and ensure that your enter...
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session a...
SYS-CON Events announced today that EnterpriseDB (EDB), the leading worldwide provider of enterprise-class Postgres products and database compatibility solutions, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. EDB is the largest provider of Postgres software and services that provides enterprise-class performance and scalability and the open source freedom to divert budget from more costly traditiona...
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
Organizations today are confounded by an avalanche of data that needs to be processed and managed on a daily basis. Through relevant use cases and a thought-provoking dialogue on an organization’s ‘Data to Decisions’ journey, Andrew Clyne, Chief Data Officer at CenturyLink Cognilytics, will reveal in his session at Big Data Expo how your organization can monetize data as a strategic asset. State-of-the-art Big Data and Advanced Analytics capabilities provided as a managed service can enable da...
There is no doubt that Big Data is here and getting bigger every day. Building a Big Data infrastructure today is no easy task. There are an enormous number of choices for database engines and technologies. To make things even more challenging, requirements are getting more sophisticated, and the standard paradigm of supporting historical analytics queries is often just one facet of what is needed. As Big Data growth continues, organizations are demanding real-time access to data, allowing immed...
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
SYS-CON Events announced today that the "First Containers & Microservices Conference" will take place June 9-11, 2015, at the Javits Center in New York City. The “Second Containers & Microservices Conference” will take place November 3-5, 2015, at Santa Clara Convention Center, Santa Clara, CA. Containers and microservices have become topics of intense interest throughout the cloud developer and enterprise IT communities.
There is no question that the cloud is where businesses want to host data. Until recently hypervisor virtualization was the most widely used method in cloud computing. Recently virtual containers have been gaining in popularity, and for good reason. In the debate between virtual machines and containers, the latter have been seen as the new kid on the block – and like other emerging technology have had some initial shortcomings. However, the container space has evolved drastically since coming on...
With worldwide spending on cloud services and infrastructure growing by 23% in 2015 to $118B, it is clear that cloud services are here to stay. Yet, the rate of cloud adoption varies by companies and markets around the world. With thousands of outages and hijacks across the Internet every day, one reason for hesitation is the faith in quality Internet performance. In his session at 16th Cloud Expo, Michael Kane, Senior Manager at Dyn, will explore how Internet performance affects your end-user...
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists will peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud en...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between confe...
Data-intensive companies that strive to gain insights from data using Big Data analytics tools can gain tremendous competitive advantage by deploying data-centric storage. Organizations generate large volumes of data, the vast majority of which is unstructured. As the volume and velocity of this unstructured data increases, the costs, risks and usability challenges associated with managing the unstructured data (regardless of file type, size or device) increases simultaneously, including end-to-...